(Q38384485)

2 September 2017

1 reference

title

Biomarkers for immunotherapy in genitourinary malignancies (English)

1 reference

2 September 2017

0 references

1 reference

Susan F Slovin

1

1 reference

2 September 2017

publication date

16 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

34

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

205-213

1 reference

Biomarkers and surrogate markers: an FDA perspective

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Cancer biomarkers: Written in blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Circulating tumor cells as biomarkers in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Prognostic or Predictive? It's Time to Get Back to Definitions!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Autoimmunity and immunotherapy for cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Immune responses to cancer: are they potential biomarkers of prognosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Immunotherapy for urological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Nivolumab plus ipilimumab in advanced melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Genetic basis for clinical response to CTLA-4 blockade in melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Intratumor heterogeneity of biomarker expression in breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Classification of current anticancer immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Cancer classification using the Immunoscore: a worldwide task force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

TNM staging in colorectal cancer: T is for T cell and M is for memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.007

10.1016/J.UROLONC.2015.02.007

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference